2DT Stock Overview
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.15 |
| 52 Week High | US$5.75 |
| 52 Week Low | US$1.46 |
| Beta | 1.35 |
| 1 Month Change | 4.67% |
| 3 Month Change | 3.41% |
| 1 Year Change | 322.13% |
| 3 Year Change | 11.47% |
| 5 Year Change | -53.97% |
| Change since IPO | -72.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2DT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -1.6% | -0.8% |
| 1Y | 322.1% | -29.6% | 1.0% |
Return vs Industry: 2DT exceeded the German Pharmaceuticals industry which returned -30.1% over the past year.
Return vs Market: 2DT exceeded the German Market which returned 1.4% over the past year.
Price Volatility
| 2DT volatility | |
|---|---|
| 2DT Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2DT has not had significant price volatility in the past 3 months.
Volatility Over Time: 2DT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,850 | Chirag Patel | amneal.com |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
| 2DT fundamental statistics | |
|---|---|
| Market cap | €1.61b |
| Earnings (TTM) | -€79.04m |
| Revenue (TTM) | €2.25b |
0.7x
P/S Ratio-20.4x
P/E RatioIs 2DT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2DT income statement (TTM) | |
|---|---|
| Revenue | US$2.39b |
| Cost of Revenue | US$1.53b |
| Gross Profit | US$863.87m |
| Other Expenses | US$947.86m |
| Earnings | -US$83.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 36.09% |
| Net Profit Margin | -3.51% |
| Debt/Equity Ratio | 4,307.3% |
How did 2DT perform over the long term?
See historical performance and comparison